These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26589590)

  • 1. Clinical implication of the serum galectin-1 expression in epithelial ovarian cancer patients.
    Chen L; Yao Y; Sun L; Zhou J; Liu J; Wang J; Li J; Tang J
    J Ovarian Res; 2015 Nov; 8():78. PubMed ID: 26589590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
    Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of lamin A but not lamin C expression in epithelial ovarian cancer cells is associated with metastasis and poor prognosis.
    Gong G; Chen P; Li L; Tan H; Zhou J; Zhou Y; Yang X; Wu X
    Pathol Res Pract; 2015 Feb; 211(2):175-82. PubMed ID: 25499720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
    Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
    Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
    Zou L; He X; Zhang JW
    Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.
    Xu Y; Wang C; Zhang Y; Jia L; Huang J
    Sci Rep; 2015 Jul; 5():12104. PubMed ID: 26175056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion.
    Kim HJ; Jeon HK; Cho YJ; Park YA; Choi JJ; Do IG; Song SY; Lee YY; Choi CH; Kim TJ; Bae DS; Lee JW; Kim BG
    Eur J Cancer; 2012 Aug; 48(12):1914-21. PubMed ID: 22386573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
    Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
    Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
    Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
    BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
    Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
    Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
    Meng Q; Duan P; Li L; Miao Y
    Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.
    Carbotti G; Orengo AM; Mezzanzanica D; Bagnoli M; Brizzolara A; Emionite L; Puppo A; Centurioni MG; Bruzzone M; Marroni P; Rossello A; Canevari S; Ferrini S; Fabbi M
    Int J Cancer; 2013 Jun; 132(11):2597-605. PubMed ID: 23169448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
    Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK
    Cancer; 2017 May; 123(6):977-984. PubMed ID: 28263384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
    Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Popa I; Bachvarov D
    Int J Oncol; 2017 Dec; 51(6):1887-1897. PubMed ID: 29039611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.
    Yuan L; Wan J; Huang C; Liang J; Liu M; Yue C; Li L
    Cancer Biomark; 2017 Dec; 21(1):97-104. PubMed ID: 29036787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.